MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces the participation of members of the company’s senior management team in three R&D and investor conferences being held virtually during May 2021.
Sensorion’s Head of CMC Gene Therapy Christine le Bec will co-chair a scientific session on the “Development of AAV Capsid Variants” at the American Society of Gene & Cell Therapy (ASGCT) Annual meeting, taking place virtually on 11-14 May 2021.
Date: Tuesday, May 11, 2021
Session: 5.30 pm to 7.15 pm EDT (11.30 pm to 1.15 am CEST)
Event: American Society of Gene & Cell Therapy Annual Meeting (ASGCT)
In addition, Sensorion’s Research Team will present an overview of the company’s Gene Therapy platform focused on hearing disorders. Poster 575 – Adeno-Associated Vector Discovery Platform for Inner Ear Disorders (ID 274) describes Sensorion’s platform for optimizing the discovery and validation of novel adeno-associated virus (AAV) gene therapy vectors for inner ear disorders with the aim of developing new proprietary therapeutic products specifically.
Date: Tuesday, May 11, 2021
Session: 8.00 am -11.00 am EDT (2.00 pm-5.00 pm CEST) Digital Gallery 516 – Neurologic Diseases
CEO Nawal Ouzren will be interviewed by research analyst Joon Lee in a fireside chat as part of the continuing Truist Securities Virtual Life Sciences series on 20 May 2021.
Date: Thursday, May 20, 2021
Fireside Chat: 12.00 noon EDT (6.00 pm CEST)
Event: Truist Securities Virtual Life Sciences series
Chief Medical Officer Géraldine Honnet will give a presentation on Sensorion’s small molecule SENS-401 entitled “Bringing a New Small Molecule to Patients for Sudden Sensorineural Hearing Loss (SSNHL) Disease” at the Inner Ear Disorders Therapeutic Summit, taking place virtually on 25-27 May 2021.
Date: Thursday, May 27, 2021
Presentation: 11.35-12.50 a.m. EDT (5.35-6.50 pm CEST)
Event: Inner Ear Disorders Therapeutic Summit
Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders. Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) for sudden sensorineural hearing loss (SSNHL). Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases enabling it to select the best targets and modalities for drug candidates. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses. Sensorion has launched three gene therapy programs, currently at preclinical stage, aimed at correcting hereditary monogenic forms of deafness including deafness caused by a mutation of the gene encoding for Otoferlin, hearing loss related to gene target GJB2 as well as Usher Syndrome Type 1 to potentially address important hearing loss segments in adults and children. The Company is potentially uniquely placed, through its platforms and pipeline of potential therapeutics, to make a lasting positive impact on hundreds of thousands of people with inner ear related disorders, a significant global unmet medical need.
This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2020 annual financial report published on April 9, 2021 and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.
+33 6 27 74 74 49
+44 74 13 82 53 10